Human immunodeficiency virus 1 retropepsin

Handbook of Proteolytic Enzymes, Second Edition: Volume 1: Aspartic and Metallo Peptidases

Volumn 1, Issue , 2004, Pages 144-153

  Dunn, Ben M ^a   Rao, Mala ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547938267     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-079611-3.50049-5     Document Type: Chapter

References (199)

1. A.M. Ainsztein and D.L. Punch (1992) Cleavage of bovine brain microtubule associated protein 2 by human immunodeficiency virus proteinase. J. Neurochem. 59 874-880.
2. P.J. Ala, E.E. Huston, R.M. Klabe, D.D. McCabe, J.L. Duke, B.D. Korant, R.J. Deloskey, P.Y.S. Lam, C.N. Hodge and C.H. Chang (1997) Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 36 1573-1580.
3. N. Almog, R. Roller, G. Arad, L. Passi-Even, M.A. Wainberg and M. Kotler (1996) A p6Pol protease fusion protein is present in mature particles of human immunodeficiency virus type 1. J. Virol. 70 7228-7232.
4. E.T. Baldwin, T.N. Bhat, S. Gulnik, B. Liu, I.A. Topol, Y. Kiso, T. Mimoto, H. Mitsuya and J.W. Erickson (1995) Structure of HIV-1 protease with KNI 272, a tight binding transition state analog containing allophenylnorstatine. Structure 3 581-590.
5. E.T. Baldwin, T.N. Bhat, B. Liu, N. Pattabiraman and J.W. Erickson (1995) Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nature Struct. Biol. 2 244-249.
6. J.S. Bardi, I. Luque and E. Freire (1997) Structure-based thermodynamic analysis of HIV-1 protease inhibitors. Biochemistry 36 6588-6596.
7. K.A. Barrie, E.E. Perez, S.L. Lamers, W.G. Farmerie, B.M. Dunn, J.W. Sleasman and M.M. Goodenow (1996) Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyprotein: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 219 407-416.
8. Z.Q. Beck, L. Hervio, P.E. Dawson, J.H. Elder and E.L. Madison (2000) Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development. Jpn J. Cancer Chemother. 274 391-401.
9. R. Betageri, J.L. Hopkins, D. Thibeault, M.J. Emmanuel, G.C. Chow, M.T. Skoog, P. de Dreu and K.A. Cohen (1993) Rapid, sensitive and efficient HPLC assays for HIV-1 proteinase. J. Biochem. Biophys. Methods 27 191-197.
10. T.N. Bhat, E.T. Baldwin, B. Liu, Y.S. Cheng and J.W. Erickson (1994) Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor. Nature Struct. Biol. 1 552-556.
11. T.N. Bhat, E.T. Baldwin, B. Liu, Y.S. Cheng and J.W. Erickson (1995) X ray structure of a tethered dimer for HIV-1 protease. Adv. Exp. Med. Biol. 362 439-444.
12. A. Billich and G. Winkler (1991) Analysis of subsite preferences of HIV-1 proteinase using MA/CA junction peptides substituted at the P3–P1′ positions. Arch. Biochem. Biophys. 290 186-190.
13. T.L. Blundell, R. Lapatto, A.F. Wilderspin, A.M. Hemmings, P.M. Hobart, D.E. Danley and P.J. Whittle (1990) The 3D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS. Trends Biochem. Sci. 15 425-430.
14. C.L. Borders Jr., J.A. Broadwater, P.A. Bekeny, J.E. Salmon, A.S. Lee, A.M. Eldridge and V.B. Pert (1994) A structural role for arginine in protein: multiple hydrogen bonds to backbone carbonyl oxygens. Protein Sci. 3 541-548.
15. P. Boross, P. Bagossi, T.D. Copeland, S. Oroszlan, J.M. Louis and J. Tözsér (1999) Effect of substrate residues on the P2′ preference of retroviral proteinases. Eur. J. Biochem. 264 921-929.
16. A.A. Bukovsky, T. Dorfman, A. Weimann and H.G. Gottlinger (1997) Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease. J. Virol. 71 1013-1018.
17. A. Caflisch, H.J. Schramm and M. Karplus (2000) Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach. J. Comput. Aided Mol. Design 14 161-179.
18. Y.D. Cai, H. Yu and K.C. Chou (1998) Artificial neural network method for predicting HIV protease cleavage sites in protein. J. Protein Chem. 17 607-615.
19. C.E. Cameron, T.W. Ridky, S. Shulenin, J. Leis, I.T. Weber, T. Copeland, A. Wlodawer, H. Burstein, D. Bizub-Bender and A.M. Skalka (1994) Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus 1 proteases. J. Biol. Chem. 269 11170-11177.
20. N. Chen, A. Morag, N. Almog, I. Blumenzweig, O. Dreazin and M. Kotler (2001) Extended nucleocapsid protein is cleaved from the Gag-Pol precursor of human immunodeficiency virus type 1. J. Gen. Virol. 82 581-590.
21. Z. Chen, Y. Li, E. Chen, D. Hall, P. Darke, C. Culberson, J.A. Shafer and L.A. Kuo (1994) Crystal structure at 1.9 Å resolution of human immunodeficiency virus (HIV) II protease complexed with L-735 524, an orally bioavailable inhibitor of the HIV proteases. J. Biol. Chem. 269 26344-26348.
22. Z. Chen, Y. Li, H. Schock, D. Hall, E. Chen and L.A. Kuo (1995) Three dimensional structure of a mutant HIV-1 protease displaying cross resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270 21433-21436.
23. Y.S.E. Cheng, M.H. McGowan, C.A. Kettner, J.V. Schloss, S. Erickson-Viitanen and F.H. Yin (1990) High level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies. Gene 87 243-248.
24. Y.S.E. Cheng, F.H. Yin, S. Foundling, D. Blomstrom and C.A. Kettner (1990) Stability and activity of human immunodeficiency virus protease comparison of the natural dimer with a homologous, single chain tethered dimer. Proc. Natl. Acad. Sci. USA 87 9660-9664.
25. K.C. Chou, A.G. Tomasselli, I.M. Reardon and R.L. Heinrikson (1996) Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method. Proteins 24 51-72.
26. E. Co, G. Koelsch, Y.Z. Lin, E. Ido, J.A. Hartsuck and J. Tang (1994) Proteolytic processing mechanisms of a miniprecursor of the aspartic protease of human immunodeficiency virus type 1. Biochemistry 33 1248-1254.
27. J.R. Collins, S.K. Burt and J.W. Erickson (1995) Rap opening in HIV-1 protease simulated by ‘activated’ molecular dynamics. Nature Struct. Biol. 2 334-338.
28. J.H. Condra, W.A. Schleif, O.M. Blahy, L.J. Gabryelski, D.J. Graham, J.C. Quintero, A. Rhodes, H.L. Robins, E. Roth, M. Shivaprakash, T. Yang, J.A. Chodakewitz, P.J. Deutsch, R.Y. Leavitt, F.E. Massari, J.W. Mellors, K.E. Squires, R.T. Steigbigel, H. Teppler and E.A. Emini (1995) in vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 569-571.
29. N.D. Cook, R.A. Jessop, P.S. Robinson, A.D. Richards and J. Kay (1991) Scintillation proximity enzyme assay. A rapid and novel assay technique applied to HIV proteinase. Adv. Exp. Med. Biol. 306 525-528.
30. T.D. Copeland, E.M. Wondrak, J. Tözsér, M.M. Roberts and S. Oroszlan (1990) Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor. Biochem. Biophys. Res. Commun. 169 310-314.
31. M. Cornelissen, R. van den Burg, F. Zorgdrager, V. Lukashov and J. Goudsmit (1997) Pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J. Virol. 71 6348-6358.
32. H.C.F. Cote, Z.L. Brumme and P.R. Harrigan (2001) Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75 589-594.
33. D.E. Danley, K.F. Geoghegan, K.G. Scheld, S.E. Lee, J.R. Merson, S.J. Hawrylik, G.A. Rickett, M.J. Ammirati and P.M. Hobart (1989) Crystallizable HIV-1 protease derived from expression of the viral pol gene in Escherichia coli. Biochem. Biophys. Res. Commun. 165 1043-1050.
34. P.L. Darke, R.F. Nutt, S.F. Brady, V.M. Garsky, T.M. Ciccarone, C.T. Leu, P.K. Lumma, R.M. Freidinger, D.F. Veber and I.S. Sigal (1988) HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun. 156 297-303.
35. C. Dash and M. Rao (2001) Interaction of a novel inhibitor from an extremophilic Bacillus sp with HIV-1 protease- implications for the mechanism of inactivation. J. Biol. Chem. 276 2487-2493.
36. S.K. Deo, J.D. Lewis and S. Daunert (2000) Bioluminescence detection of proteolytic bond cleavage by using recombinant aequorin. Anal. Biochem. 281 87-94.
37. F. di Marzo Veronese, T.D. Copeland, A.L. DeVico, R. Rahman, S. Oroszlan, R.C. Gallo and M.G. Sarngadharan (1986) Characterization of highly immunogenic p66/p51 as the reverse transcriptase of hTLV-III/LAV. Science 231 1289-1291.
38. B.D. Dorsey, R.B. Levin, S.L. McDaniel, J.P. Vacca, J.P. Guare, P.L. Darke, J.A. Zugay, E.A. Emini, W.A. Schleif, J.C. Quintero, J.H. Lin, I.-W. Chen, M.K.M.D. Holloway, P. Fitzgerald, M.G. Axel, D. Ostovic, P.S. Anderson and J.R. Huff (1994) L 735 524 the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37 3443-3451.
39. L. Doyon, D. Thibeault, G. Mckercher, L. Pilote and D. Lamarre (1997) Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71 1089-1096.
40. B.M. Dunn, A. Gustchina, A. Wlodawer and J. Kay (1994) Subsite preferences of retroviral proteinases. Methods Enzymol. 241 254-278.
41. S. Erickson-Viitanen, J. Manfredi, P. Viitanen, D.E. Tribe, R. Tritch, C.A. Hutchison III, D.D. Loeb and R. Swanstrom (1989) Cleavage of HIV-1 gag polyprotein synthesized in vitro sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses 5 577-591.
42. J. Ermolieff, X.L. Lin and J. Tang (1997) Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. Biochemistry 36 12364-12370.
43. D.B. Evans, A.F. Vosters, T.J. McQuade and S.K. Sharma (1992) An ultrasensitive human immunodeficiency virus type 1 protease radioimmuno rate assay with a potential for monitoring blood levels of protease inhibitors in acquired immunodeficiency disease syndrome patients. Anal. Biochem. 206 192-288.
44. P.M.D. Fitzgerald, B.M. McKeever, J.F. VanMiddlesworth, J.P. Springer, J.C. Heimbach, C.T. Leu, W.K. Herber, R.A.F. Dixon and P.L. Darke (1990) Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl pepstatin at 2.0 Å resolution. J. Biol. Chem. 265 14209-14219.
45. G. Fontenot, K. Johnston, J.C. Cohen, W.R. Gallaher, J. Robinson and R.B. Luftig (1992) PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. Virology 190 1-10.
46. J. Freund, R. Kellner, J. Konvalinka, V. Wolber, H.G. Kräusslich and H.R. Kalbitzer (1994) A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease. Eur. J. Biochem. 223 589-593.
47. K. Gaedigk-Nitschko, A. Schon, G. Wachinger, V. Erfle and B. Kohleisen (1995) Cleavage of recombinant and cell derived human immunodeficiency virus 1 (HIV-1) Nef protein by HIV-1 protease. FEBS Lett. 357 275-278.
48. L. Goobar, U.H. Danielson, P. Brodin, T. Grundstrom, B. Oberg and E. Norrby (1991) High yield purification of HIV-1 proteinase expressed by a synthetic gene in Escherichia coli. Protein Expr. Purif. 2 15-23.
49. M.M. Goodenow, G. Bloom, S.L. Rose, S.M. Pomeroy, P.O. O'Brien, E.E. Perez, J.W. Sleasman and B.M. Dunn (2002) Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease. Virology 292 137-149.
50. B.J. Graves, M.H. Hatada, J.K. Miller, M.C. Graves, S. Roy, C.M. Cook, A. Krohn, J.A. Martin and N.A. Roberts (1991) The three dimensional x ray crystal structure of HIV-1 protease complexed with a hydroxyethylene inhibitor. Adv. Exp. Med. Biol. 306 455-460.
51. M.C. Graves, J.J. Lim, M.A. Zicopoulos, T.J. Stoller, M.C. Miedel, Y.-C.E. Pan, W. Danho and C.M. Nalin (1989) Expression and characterization of human immunodeficiency virus-1 protease. V. Kostka (Eds) Proteases of Retroviruses Berlin: Walter de Gruyter 83-92.
52. M.C. Graves, M.C. Meidel, Y.C. Pan, M. Manneberg, H.W. Lahm and F. Gruninger-Leitch (1990) Identification of a human immunodeficiency virus-1 protease cleavage site within the 66 000 Dalton subunit of reverse transcriptase. Biochem. Biophys. Res. Commun. 168 30-36.
53. J. Greer, J.W. Erickson, J.J. Baldwin and M.D. Varney (1994) Application of the three dimensional structures of protein target molecules in structure based drug design. J. Med. Chem. 37 1035-1054.
54. J.H. Griffiths, L.H. Phylip, J. Konvalinka, P. Strop, A. Gustchina, A. Wlodawer, R.J. Davenport, R. Briggs, B.M. Dunn and J. Kay (1992) Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing hydrophobic*hydrophobic or aromatic*pro cleavage sites. Biochemistry 31 5193-5200.
55. C. Guenet, R.A. Leppik, J.T. Pelton, K. Moelling, W. Lovenberg and B.A. Harris (1989) HIV-1 protease mutagenesis of asparagine 88 indicates a domain required for dimer formation. Eur. J. Pharmacol. 172 443-451.
56. S.V. Gulnik, L.I. Suvorov, B.S. Liu, B. Yu, B. Anderson, H. Mitsuya and J.W. Erickson (1995) Kinetic characterization and cross resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34 9282-9287.
57. M.E. Gustafson, K.D. Junger, B.A. Foy, J.A. Baez, B.F. Bishop, S.H. Rangwala, M.L. Michener, R.M. Leimgruber, K.A. Houseman, R.A. Mueller, B.K. Matthews, P.O. Olins, R.W. Grabner and A. Hershman (1995) Large scale production of HIV-1 protease from Escherichia coli using selective extraction and membrane fractionation. Protein Expr. Purif. 6 512-518.
58. A. Gustchina and I.T. Weber (1990) Comparison of inhibitor binding in HIV-1 protease and in nonviral aspartic protease: the role of the flap. FEBS Lett. 269 269-272.
59. A. Gustchina, C. Sansom, M. Prevost, J. Richelle, S.Y. Wodak, A. Wlodawer and I.T. Weber (1994) Energy calculations and analysis of HIV-1 protease inhibitor crystal structures. Protein Eng. 7 309-317.
60. W.J. Harte, S. Swaminathan, M.M. Mansuri, J.C. Martin, I.E. Rosenberg and D.L. Beveridge (1990) Domain communication in the dynamical structure of human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. USA 87 8864-8868.
61. J.C. Heimbach, V.M. Garsky, S.R. Michelson, R.A.F. Dixon, I.S. Sigal and P.L. Darke (1989) Affinity purification of the HIV-1 protease. Biochem. Biophys. Res. Commun. 164 955-960.
62. L.E. Henderson, T.D. Copeland, R.C. Sowder, A.M. Schultz and S. Oroszlan (1988) Analysis of proteins and peptides purified from sucrose gradient banded HTLV-III. D. Bolognesi (Eds) Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy New York: Alan R. Liss 135-147.
63. D.D. Ho, A.U. Neumann, A.S. Perelson, L.J. Chen and M. Markowitz (1995) Rapid turnover of plasma virions and CD3 lymphocytes in HIV-1 infection. Nature 373 123-126.
64. P.J. Hoeprich (1994) Chemical synthesis of the aspartic proteinase from human immunodeficiency virus (HIV). Methods Mol. Biol. 36 287-304.
65. B. Höner, R.L. Shoeman and P. Traub (1991) Human immunodeficiency virus type 1 protease microinjected into cultured human skin fibroblasts cleaves vimentin and affects cytoskeletal and nuclear architecture. J. Cell Sci. 100 799-807.
66. B. Höner, R.L. Shoeman and P. Traub (1992) Degradation of cytoskeletal proteins by the human immunodeficiency virus type 1 protease. Cell Biol. Int. Rep. 16 603-612.
67. L. Hong, A. Treharne, J.A. Hartsuck, S. Foundling and J. Tang (1996) Crystal structures of complexes of a peptidic inhibitor with wild type and two mutant HIV-1 proteases. Biochemistry 35 10627-10633.
68. L. Hong, J.A. Hartsuck, S. Foundling, J. Ermolieff and J. Tang (1998) Active-site mobility in human immunodeficiency virus type 1 protease as demonstrated by crystal structure of A28S mutant. Protein Sci. 7 300-305.
69. S.S. Hoog, B. Zhao, E. Winborne, S. Fisher, D.W. Green, R.L. DesJarlais, K.A. Newlander, J.F. Callahan, M.L. Moore, W.F. Huffman and S.S. Abdel-Meguid (1995) A check on rational drug design crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma turn mimetic inhibitor. J. Med. Chem. 38 3246-3252.
70. Z. Hostomsky, K. Appelt and R.C. Ogden (1989) High level expression of self processed HIV-1 protease in Escherichia coli using a synthetic gene. Biochem. Biophys. Res. Commun. 161 1056-1063.
71. J.O. Hui, A.G. Tomasselli, I.M. Reardon, J.M. Lull, D.P. Brunner, C.S. Tomich and R.L. Heinrikson (1993) Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies. J. Protein Chem. 12 323-327.
72. L.J. Hyland, B.D. Dayton, M.L. Moore, A.Y.L. Shu, J.R. Heys and T.D. Meek (1990) A radiometric assay for HIV-1 protease. Anal. Biochem. 188 408-415.
73. R. Ishima, D.I. Freedberg, Y.X. Wang, J.M. Louis and D.A. Torchia (1999) Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Structure 7 1047-1055.
74. H. Jacobsen, K. Yasargil, D.L. Winslow, J.C. Craig, A. Krohn, I.B. Duncan and J. Mous (1995) Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31 8959. Virology 206 527-534.
75. M. Jaskolski, A.G. Tomasselli, T.K. Sawyer, D.G. Staples, R.L. Heinrikson, J. Schneider, S.B.H. Kent and A. Wlodawer (1991) Structure at 2.5 Å resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene based inhibitor. Biochemistry 30 1600-1609.
76. H. Jhoti, O.M. Singh, M.P. Weir, R. Cooke, P. Murray-Rust and A. Wonacott (1994) X ray crystallographic studies of a series of penicillin derived asymmetric inhibitors of HIV-1 protease. Biochemistry 33 8417-8427.
77. R. Kantor, R. Machekano, M.J. Gonzalez, K. Dupnik, J.M. Schapiro and R.W. Shafer (2001) Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. 29 296-299.
78. A.H. Kaplan, J.A. Zack, M. Knigge, DA. Paul, D.J. Kempf, D.W. Norbeck and R. Swanstrom (1993) Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67 4050-4055.
79. A.H. Kaplan, S.S. Michael, R.F. Wehbie, M.S. Knigge, D.A. Paul, L. Everitt, D.J. Kempf, D.W. Norbeck, J.W. Erickson and R. Swanstrom (1994) Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91 5597-5601.
80. A.H. Kaplan, M. Manchester and R. Swanstrom (1994) The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68 6782-6786.
81. A.H. Kaplan, M. Manchester, T. Smith, Y.L. Yang and R. Swanstrom (1996) Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication. J. Virol. 70 5840-5844.
82. D.B. Kassel, M.D. Green, R.S. Wehbie, R. Swanstrom and J. Berman (1995) HIV-1 protease specificity derived from a complex mixture of synthetic substrates. Anal. Biochem. 228 259-266.
83. D.J. Kempf, K.C. Marsh, J.F. Denissen, E. McDonald, S. Vasavanonda, C.A. Flentge, B.E. Green, L. Fino, C.H. Park, X.P. Kong, N.E. Wideburg, A. Saldivar, L. Ruiz, W.M. Kati, H.L. Shaw, T. Robins, K.D. Stewart, A. Hsu, J.J. Plattner, J.M. Leonard and D.W. Norbeck (1995) ABT 538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92 2484-2488.
84. J. Konvalinka, P. Strop, J. Velek, V. Cerna, V. Kostka, L.H. Phylip, A.D. Richards, B.M. Dunn and J. Kay (1990) Sub site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1. FEBS Lett. 268 35-38.
85. M. Kotler, G. Arad and S.H. Hughes (1992) Human immunodeficiency virus type 1 ga g-protease fusion proteins are enzymatically active. J. Virol. 66 6781-6783.
86. M.J. Kozal, N. Shah, N.P. Shen, R. Yang, R. Fucini, T.C. Merigan, D.D. Richman, D. Morris, E.R. Hubbell, M. Chee and T.R. Gingeras (1996) Extensive polymorphisms observed in HIV-1 clade B protease gene using high density oligonucleotide arrays. Nature Med. 2 753-759.
87. G.A. Krafft and G.T. Wang (1994) Synthetic approaches to continuous assays of retroviral proteases. Methods Enzymol. 2A 70-86.
88. H.G. Kräusslich, R.H. Ingraham, M.T. Skoog, E. Wimmer, P.V. Pallai and C.A. Carter (1989) Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc. Natl. Acad. Sci. USA 86 807-811.
89. R. Lapatto, T. Blundell, A. Hemmings, J. Overington, A. Wilderspin, S. Wood, J. Merson, P.J. Whittle, D.E. Danley, K.F. Geoghegan, S.J. Hawrylik, S.E. Lee, K.G. Scheld and P.M. Hobart (1989) X ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 342 299-302.
90. W.J. Lech, G. Wang, Y.L. Yang, Y. Chee, K. Dorman, D. McCrae, L.C. Lazzeroni, J.W. Erickson, J.S. Sinsheimer and A.H. Kaplan (1996) In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor resistant variants in untreated subjects. J. Virol. 70 2038-2043.
91. M.M. Lightfoote, J.E. Coligan, T.M. Folks, A.S. Fauci, M.A. Martin and S. Venkatesan (1986) Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J. Virol. 60 771-775.
92. Y. Lin, X. Lin, L. Hong, S. Foundling, R.L. Heinrikson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B.M. Dunn and J. Tang (1995) Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease relationship to drug resistance. Biochemistry 34 1143-1152.
93. H. Liu, F. Muller Plathe and W.F. van Gunsteren (1996) A combined quantum/classical molecular dynamics study of the catalytic mechanism of HIV protease. J. Mol. Biol. 261 454-469.
94. D.D. Loeb, R. Swanstrom, L. Everitt, M. Manchester, S.E. Stamper and C.A. Hutchison III (1989) Complete mutagenesis of the HIV-1 protease. Nature 340 397-400.
95. J.M. Louis, C.A.D. Smith, E. Wondrak, P.T. Mora and S. Oroszlan (1989) Substitution mutations of the highly conserved arginine 87 of HIV-1 protease result in loss of proteolytic activity. Biochem. Biophys. Res. Commun. 164 30-38.
96. J.M. Louis, N.T. Nashed, K.D. Parris, A.R. Kimmel and D.M. Jerina (1994) Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag Pol polyprotein. Proc. Natl. Acad. Sci. USA 91 7970-7974.
97. J.M. Louis, F. Dyda, N.T. Nashed, A.R. Kimmel and D.R. Davies (1998) Hydrophilic peptides derived from the transframe region of gag-pol inhibit the HIV-1 protease. Biochemistry 37 2105-2110.
98. J.M. Louis, G.M. Clore and A.M. Gronenborn (1999) Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nature Struct. Biol. 6 868-875.
99. R.B. Luftig and L.D. Lupo (1994) Viral interactions with the host cell cytoskeleton: the role of retroviral proteases. Trends Microbiol. 2 178-182.
100. I. Luque, M.J. Todd, J. Gomez, N. Semo and E. Freire (1998) Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. Biochemistry 37 5791-5797.
101. B. Mahalingam, J.M. Louis, J. Hung, R.W. Harrision and I.T. Weber (2001) Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43 455-464.
102. B. Mahalingam, P. Boross, Y.-F. Wang, J.M. Louis, C.C. Fischer, J. Tözsér, R.W. Harrison and I.T. Weber (2002) Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins 48 107-116.
103. N. Margolin, W. Heath, E. Osborne, M. Lai and C. Vlahos (1990) Substitutions at the P2′ site of gag p17 p24 affect cleavage efficiency by HIV-1 protease. Biochem. Biophys. Res. Commun. 167 554-560.
104. N. Margolin, A. Dee, M. Lai and C. Vlahos (1991) Purification of recombinant HIV-1 protease. Prep. Biochem. 21 163-173.
105. M. Markowitz, H. Mo, D.J. Kempf, D.W. Norbeck, T.N. Bhat, J.W. Erickson and D.D. Ho (1995) Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT 538, a novel protease inhibitor. J. Virol. 69 701-706.
106. E. Matayoshi, G.T. Wang, G.A. Krafft and J.W. Erickson (1990) Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247 954-958.
107. A.M. Mildner, D.J. Rothrock, J.W. Leone, C.A. Bannow, J.M. Lull, I.M. Reardon, J.L. Sarcich, W.J. Howe, C.S.C. Tomich, C.W. Smith, R.L. Heinrikson and A.G. Tomasselli (1994) The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 33 9405-9413.
108. M. Miller, J. Schneider, B.K. Sathyanarayana, M.V. Toth, G.R. Marshall, L. Clawson, L. Selk, S.B.H. Kent and A. Wlodawer (1989) Structure of complex of synthetic HIV-1 protease with a substrate based inhibitor at 2.3 Å resolution. Science 246 1149-1152.
109. R.C. Milton, S.C. Milton and S.B.H. Kent (1992) Total chemical synthesis of a D enzyme the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity. Science 256 1445-1448.
110. A. Molla, M. Korneyeva, Q. Gao, S. Vasavanonda, P.J. Schipper, H.M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G.R. Granneman, D.D. Ho, C.A.B. Boucher, J.M. Leonard, D.W. Norbeck and D.J. Kempf (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2 760-766.
111. M.D. Moody, S.C. Pettit, W. Shao, L. Everitt, D.D. Loeb, C.A. Hutchison III and R. Swanstrom (1995) A side chain at position 48 of the human immunodeficiency virus type 1 protease flap provides an additional specificity determinant. Virology 207 475-485.
112. K.H. Murthy, E.L. Winborne, M.D. Minnich, J.S. Culp and C. Debouck (1992) The crystal structures at 2.2 Å resolution of hydroxyethylene based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations. J. Biol. Chem. 267 22770-22778.
113. N.T. Nashed, J.M. Louis, J.M. Sayer, E.M. Wondrak, P.T. Mora, S. Oroszlan and D.M. Jerina (1989) Continuous spectrophotometric assay for retroviral proteases of HIV-1 and AMV. Biochem. Biophys. Res. Commun. 163 1079-1085.
114. L.K. Nicholson, T. Yamazaki, D.A. Torchia, S. Grzesiek, A. Bax, S.J. Stahl, J.D. Kaufman, P.T. Wingfield, P.Y.S. Lam, P.K. Jadhav, C.N. Hodge, P.J. Domaille and C.-H. Chang (1995) Flexibility and function in HIV-1 protease (see comments). Nature Struct. Biol. 2 274-280.
115. M. Oswald and K. von der Helm (1991) Fibronectin is a non-viral substrate for the HIV proteinase. FEBS Lett. 292 298-300.
116. M.J. Otto, S. Garber, D.L. Winslow, C.D. Reid, P. Aldrich, P.K. Jadhav, C.E. Patterson, C.E. Hodge and Y.N. Cheng (1993) In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C 2 symmetrical inhibitors of HIV type 1 protease. Proc. Natl. Acad. Sci. USA 90 7543-7547.
117. K. Partin, G. Zybarth, L. Ehrlich, M. DeCrombrugghe, E. Wimmer and C. Carter (1991) Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 88 4776-4780.
118. S. Pazhanisamy, C.M. Stuver and D.J. Livingston (1995) Automation of a high performance liquid chromatography based enzyme assay evaluation of inhibition constants for human immunodeficiency virus 1 protease inhibitors. Anal. Biochem. 229 48-53.
119. S. Pazhanisamy, C.M. Stuver, A.B. Cullinan, N. Margolin, B.G. Rao and D.J. Livingston (1996) Kinetic characterization of human immunodeficiency virus type 1 protease resistant variants. J. Biol. Chem. 271 17979-17985.
120. L.H. Pearl and W.R. Taylor (1987) A structural model for the retroviral proteases. Nature 329 351-354.
121. I.V. Pechik, A.E. Gustchina, N.S. Andreeva and A.A. Fedorov (1989) Possible role of sme groups in the structure and function of HIV-1 protease as revealed by molecular modeling studies. FEBS Lett. 247 118-122.
122. A.G. Peranteau, P. Kuzmic, Y. Angell, C. Garcia-Echeverria and D.H. Rich (1995) Increase in fluorescence upon the hydrolysis of tyrosine peptide: application to proteinase assays. Anal. Biochem. 227 242-245.
123. S.C. Pettit, N. Sheng, R. Tritch, S. Erickson-Viitanen and R. Swanstrom (1998) The regulation of sequential processing of HIV-1 gag by the viral protease. Adv. Exp. Med. Biol. 436 15-25.
124. L.H. Phylip, A.D. Richards, J. Kay, J. Konvalinka, P. Strop, I. Bláha, J. Velek, V. Kostka, A.J. Ritchie, A.V. Broadhurst, W.G. Farmerie, P.E. Scarborough and B.M. Dunn (1990) Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases. Biochem. Biophys. Res. Commun. 171 439-444.
125. L.H. Phylip, J.S. Mills, B.F. Parten, B.M. Dunn and J. Kay (1992) Intrinsic activity of precursor forms of HIV-1 proteinase. FEBS Lett. 314 449-454.
126. R.A. Poorman, A.G. Tomasselli, R.L. Heinrikson and F.J. Kezdy (1991) A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. J. Biol. Chem. 266 14554-14561.
127. D.J.T. Porter, M.H. Hanlon, L.H. Carter, D.P. Danger and E.S. Furfine (2001) Effectors of HIV-1 protease peptidolytic activity. Biochemistry 40 11131-11139.
128. M. Prabu-Jeyabalan, E. Nalivaika and C.A. Schiffer (2000) How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. Mol. Biol. 301 1207-1220.
129. M. Prabu-Jeyabalan, E. Nalivaika and C.A. Schiffer (2002) Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes. Structure 10 369-381.
130. J.P. Priestle, A. Fassler, J. Rosel, M. Blomley, P. Strop and M.G. Grutter (1995) Comparative analysis of the X ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 3 381-389.
131. L. Ratner, W. Haseltine, R. Patarca, K.J. Livak, B. Starcich, S.F. Josephs, E.R. Dorna, J.A. Rafalski, E.A. Whitehorn, K. Baumeister, L. Ivanoff, S.R. Petteway, M.L. Pearson, J.A. Lauttenberger, T.S. Papas, J. Ghrayeb, N.T. Chang, R.C. Gallo and F. Wong-Staal (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313 277-285.
132. A.D. Richards, R. Roberts, B.M. Dunn, M.C. Graves and J. Kay (1989) Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett. 247 113-117.
133. A.D. Richards, L.H. Phylip, W.G. Farmerie, P.E. Scarborough, A. Alvarez, B.M. Dunn, P.H. Hirel, J. Konvalinka, P. Strop, L. Pavlickova, V. Kostka and J. Kay (1990) Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J. Biol. Chem. 265 7733-7736.
134. S.W. Rick, J.W. Erickson and J.W. Burt (1998) Reaction path and free energy calculations of the transition between alternate conformations of HIV-1 protease. Proteins 32 7-16.
135. T.W. Ridky and J. Leis (1995) Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270 29621-29623.
136. T.W. Ridky, A. Kikonyogo, J. Leis, S. Gulnik, T. Copeland, J. Erickson, A. Wlodawer, I. Kurinov, R.W. Harrison and I.T. Weber (1998) Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry 37 13835-13845.
137. J. Rittenhouse, M.C. Turon, R.J. Helfrich, K.S. Albrecht, D. Weigl, R.L. Simmer, F. Mordini, J. Erickson and W.E. Kohlbrenner (1990) Affinity purification of HIV-1 and HIV-2 proteases from recombinant E. coli strains using pepstatin agarose. Biochem. Biophys. Res. Commun. 171 60-66.
138. Y. Rivière, V. Blank, P. Kourilsky and A. Israel (1991) Processing of the precursor of NF B by the HIV-1 protease during acute infection. Nature 350 625-626.
139. N.A. Roberts, J.A. Martin, D. Kinchington, A.V. Broadhurst, J.C. Craig, I.B. Duncan, S.A. Galpin, B.K. Handa, J. Kay, A. Kröhn, R.W. Lambert, J.H. Merrett, J.S. Mills, K.E.B. Parkes, S. Redshaw, A.J. Ritchie, D.L. Taylor, G.J. Thomas and P.J. Machin (1990) Rational design of peptide based HIV proteinase inhibitors. Science 248 358-361.
140. R.B. Rose, C.S. Craik, N.L. Douglas and R.M. Stroud (1996) Three dimensional structures of HIV-1 and SIV protease product complexes. Biochemistry 35 12933-12944.
141. R.E. Rose, Y.F. Gong, J.A. Greytok, C.M. Bechtold, B.J. Terry, B.S. Robinson, M. Alam, R.J. Colonno and P.F. Lin (1996) Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93 1648-1653.
142. R.B. Rose, C.S. Craik and R.M. Stroud (1998) Domain flexibility in retroviral proteases – structural implications for drug resistant mutations. Biochemistry 37 2607-2621.
143. C.D. Rosin, R.K. Belew, G.M. Morris, A.J. Olson and D.S. Good-sell (1999) Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease. Proc. Natl. Acad. Sci. USA 96 1369-1374.
144. E.K. Ross, T.R. Fuerst, J.M. Orenstein, T. O'Neill, M.A. Martin and S. Venkatesan (1991) Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease. AIDS Res. Hum. Retroviruses 7 475-483.
145. E. Rutenber, E.B. Fauman, R.J. Keenan, S. Fong, P.S. Furth, P.R. Ortiz de Montellano, E. Meng, I.D. Kuntz, D.L. DeCamp, R. Salto, J.R. Rosé, C.C. Craik and R.M. Stroud (1993) Structure of a non peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure based drug design. J. Biol. Chem. 268 15343-15346.
146. R. Sanchez-Pescador, M.D. Power, P.J. Barr, K.S. Steimer, M.M. Stempien, S.L. Brown-Shimer, W.W. Gee, A. Renard, A. Randolph, J.A. Levy, D. Dino and P.A. Luciw (1985) Nucleotide sequence and expression of an AIDS associated retrovirus (ARV-2). Science 227 4686-4849.
147. V.V. Sardana, A.J. Schlabach, P. Graham, B.L. Bush, J.H. Condra, J.C. Culberson, L. Gotlib, D.J. Graham, N.E. Kohl, R.L. LaFemina, C.L. Schneider, B.S. Wolanski, J.A. Wolfgang and E.A. Emini (1994) Human immunodeficiency virus type 1 protease inhibitor: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry 33 2004-2010.
148. J. Schneider and S.B.H. Kent (1988) Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease. Cell 54 363-368.
149. S. Seelmeier, H. Schmidt, V. Turk and K. von der Helm (1988) Human immunodeficiency virus has an aspartic type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA 85 6612-6616.
150. Y.Y. Sham, Z.T. Chu, H. Tao and A. Warshel (2000) Examining methods for calculations of binding free energies: LRA, LIE, PDLD-LRA, and PDLD/S-LRA calculations of ligands binding to an HIV protease. Proteins 39 393-407.
151. W. Shao, L. Everitt, M. Manchester, D.D. Loeb, C.A. Hutchison and R. Swanstrom (1997) Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc. Natl. Acad. Sci. USA 94 2243-2248.
152. R.L. Shoeman, B. Höner, T.J. Stoller, C. Kesselmeier, M.C. Miedel, P. Traub and M.C. Graves (1990) Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc. Natl. Acad. Sci. USA 87 6336-6340.
153. R.L. Shoeman, C. Sachse, B. Höner, E. Mothes, M. Kaufmann and P. Traub (1993) Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin. Am. J. Pathol. 142 221-230.
154. A.M. Silva, R.E. Cachau, E.T. Baldwin, S. Gulnik, H.L. Sham and J.W. Erickson (1995) Molecular dynamics of HIV-1 protease in complex with a difluoroketone containing inhibitor implications for the catalytic mechanism. Adv. Exp. Med. Biol. 362 451-454.
155. J. Stebbins and C. Debouck (1994) Expression systems for retroviral proteases. Methods Enzymol. 241 13-16.
156. D. Stoffler, M.F. Sanner, G.M. Morris, A.J. Olson and D.S. Good-sell (2002) Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance. Proteins 48 63-74.
157. V. Stoll, W.Y. Qin, K.D. Stewart, C. Jakob, C. Park, K. Walter, R.L. Simmer, R. Helfrich, D. Bussiere, J. Kao, D. Kempf, H.L. Sham and D.W. Norbeck (2002) X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg. Med. Chem. 10 2803-2806.
158. A.L. Swain, M.M. Miller, J. Green, D.H. Rich, J. Schneider, S.B.H. Kent and A. Wlodawer (1990) X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate based hydroxyethylamine inhibitor. Proc. Natl. Acad. Sci. USA 87 8805-8809.
159. R. Swanstrom and J. Eron (2000) Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86 145-170.
160. W.R. Taylor (1994) Protein structure modelling from remote sequence similarity. J. Biotechnol. 35 281-291.
161. N. Thanki, J.K. Rao, S.I. Foundling, W.J. Howe, J.B. Moon, J.O. Hui, A.G. Tomasselli, R.L. Heinrikson, S. Thaisrivongs and A. Wlodawer (1992) Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene containing inhibitor: comparisons with molecular modeling. Protein Sci. 1 1061-1072.
162. M. Tisdale, R.E. Myers, B. Maschera, N.R. Parry, N.M. Oliver and E.D. Blair (1995) Cross resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39 1704-1710.
163. M.J. Todd, I. Luque, A. Velbzques-Campoy and E. Freire (2000) Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 39 11876-11883.
164. A.G. Tomasselli and R.L. Heinrikson (1994) Specificity of retroviral protease: an analysis of viral and nonviral protein substrates. Methods Enzymol. 241 279-301.
165. A.G. Tomasselli, J.O. Hui, T.K. Sawyer, D.J. Staples, C.A. Bannow, I.M. Reardon, V.K. Chaudhary, C.M. Fryling, I. Pastan, D.J. Fitzgerald and R.L. Heinrikson (1990) Proteases from human immunodeficiency virus and avian myeloblastosis virus show distinct specificities in hydrolysis of multidomain protein substrates. J. Virol. 64 3157-3161.
166. A.G. Tomasselli, J.O. Hui, T.K. Sawyer, D.J. Staples, D.J. FitzGerald, V.K. Chaudhary, I. Pastan and R.L. Heinrikson (1990) Interdomain hydrolysis of a truncated Pseudomonas exotoxin by the human immunodeficiency virus 1 protease. J. Biol. Chem. 265 408-413.
167. A.G. Tomasselli, J.O. Hui, T.K. Sawyer, D.J. Staples, C.A. Bannow, I.M. Reardon, W.J. Howe, D.L. DeCamp, C.S. Craik and R.L. Heinrikson (1990) Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J. Biol. Chem. 265 14675-14683.
168. A.G. Tomasselli, W.J. Howe, J.O. Hui, T.K. Sawyer, I.M. Reardon, D.L. DeCamp, C.S. Craik and R.L. Heinrikson (1991) Calcium free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2. Proteins 10 1-9.
169. A.G. Tomasselli, J.O. Hui, L. Adams, J. Chosay, D.D. Lowery, B. Greenberg, A. Yem, M.R. Deibel Jr., H.A. Zurcher-Neely and R.L. Heinrikson (1991) Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus. J. Biol. Chem. 266 14548-14553.
170. A.G. Tomasselli, J.L. Sarcich, L.J. Barrett, I.M. Reardon, W.J. Howe, D.B. Evans, S.K. Sharma and R.L. Heinrikson (1993) Human immunodeficiency virus type 1 reverse transcriptase and ribonuclease H as substrates of the viral protease. Protein Sci. 2 2167-2176.
171. T.A. Tomaszek, V.W. Magaard, H.G. Bryan, M.L. Moore and T.D. Meek (1990) Chromophoric peptide substrates for the spectrophotometric assay of HIV-1 protease. Biochem. Biophys. Res. Commun. 168 274-280.
172. M.V. Toth and G.R. Marshall (1990) A simple, continuous fluorometric assay for HIV protease. Int. J. Pept. Protein Res. 36 544-550.
173. J. Tözsér, I. Bláha, T.D. Copeland, E.M. Wondrak and S. Oroszlan (1991) Comparison of the HIV-1 and HIV 2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 281 77-80.
174. J. Tözsér, A. Gustchina, I.T. Weber, I. Bl' aha, E.M. Wondrak and S. Oroszlan (1991) Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett. 279 356-360.
175. J. Tözsér, I.T. Weber, A. Gustchina, I. Bl' aha, T.D. Copeland, J.M. Louis and S. Oroszlan (1992) Kinetic and modeling studies of S3 S3′ subsites of HIV proteinases. Biochemistry 31 4793-4800.
176. J. Tözsér, P. Bagossi, I.T. Weber, J.M. Louis, T.D. Copeland and S. Oroszlan (1997) Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity. J. Biol. Chem. 272 16807-16814.
177. J.E. Vance, D.A. Leblanc, P. Wingfield and R.E. London (1997) Conformational selectivity of HIV-1 protease cleavage of X-Pro peptide bonds and its implications. J. Biol. Chem. 272 15603-15606.
178. M.D. Varney, K. Appelt, V. Kalish, M.R. Reddy, J. Tatlock, C.L. Palmer, W.H. Romines, B.W. Wu and L. Musick (1994) Crystal structure based design and synthesis of novel C terminal inhibitors of HIV protease. J. Med. Chem. 37 2274-2284.
179. J. Vondrasek and A. Wlodawer (1996) New database (letter). Science 272 337-338.
180. J. Vondrasek and A. Wlodawer (1997) Database of HIV proteinase structures. Trends Biochem. Sci. 22 183.
181. J. Vondrasek, C.P. van Buskirk and A. Wlodawer (1997) Database of three-dimensional structures of HIV proteinases. Nature Struct. Biol. 4 8.
182. S. Wain-Hobson, P. Sonigo, O. Danos, S. Cole and M. Alizon (1985) Nucleotide sequence of the AIDS virus, LAV. Cell 40 9-17.
183. M. Wallin, J. Deinum, L. Goobar and U.H. Danielson (1990) Proteolytic cleavage of microtubule associated proteins by retroviral proteinases. J. Gen. Virol. 71 1985-1991.
184. Y.X. Wang, D.I. Freedberg, S. Grzesiek, D.A. Torchia, P.T. Wingfield, J.D. Kaufman, S.J. Stahl, C.H. Chang and C.N. Hodge (1996) Mapping hydration water molecules in the HIV-1 protease/DMP323 complex in solution by NMR spectroscopy. Biochemistry 35 12694-12704.
185. I.T. Weber (1991) Modeling of structure of human immunodeficiency virus 1 protease with substrate based on crystal structure of Rous sarcoma virus protease. Methods Enzymol. 202 727-741.
186. I.T. Weber, M. Miller, M. Jaskolski, J. Leis, A.M. Skalka and A. Wlodawer (1989) Molecular modeling of the HIV-1 protease and its substrate binding site. Science 243 928-931.
187. I.T. Weber, J. Wu, J. Adomat, R.W. Harrison, A.R. Kimmel, E.M. Wondrak and J.M. Louis (1997) Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate – interactions with frequently occurring glutamic acid residue at P2′ position of substrate. Eur. J. Biochem. 249 523-530.
188. R. Welker, H. Kottler, H.R. Kalbitzer and H.G. Kräusslich (1996) Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 219 228-236.
189. S.I. Wilson, L.H. Phylip, J.S. Mills, S.V. Gulnik, J.W. Erickson, B.M. Dunn and J. Kay (1997) Escape mutants of HIV-1 proteinase: enzymatic efficiency and susceptibility to inhibition. Biochim. Biophys. Acta 1339 113-125.
190. A. Wlodawer (2002) Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 53 595-614.
191. A. Wlodawer and J.W. Erickson (1993) Structure based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62 543-585.
192. A. Wlodawer and A. Gustchina (2000) Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta 1477 16-34.
193. A. Wlodawer, M. Miller, M. Jaskolski, B.K. Sathyanarayana, E. Baldwin, I.T. Weber, L.M. Selk, L. Clawson, J. Schneider and S.B.H. Kent (1989) Conserved folding in retroviral protease: crystal structure of a synthetic HIV-1 protease. Science 245 616-621.
194. E.M. Wondrak and J.M. Louis (1996) Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 35 12957-12962.
195. E.M. Wondrak, N.T. Nashed, M.T. Haber, D.M. Jerina and J.M. Louis (1996) A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation. J. Biol. Chem. 271 4477-4481.
196. D. Zhang, N. Zhang, M.M. Wick and R.A. Byrn (1995) HIV type 1 protease activation of NF B within T lymphoid cells. AIDS Res. Hum. Retroviruses 11 223-230.
197. R. Zutshi, J. Franciskovich, M. Shultz, B. Schweitzer, P. Biship, M. Wilson and J. Chmielewski (1997) Targeting the dimerization interface of HIV-1 protease – inhibition with cross-linked interfacial peptides. J. Am. Chem. Soc. 119 4841-4845.
198. G. Zybarth and C. Carter (1995) Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag Pol influence PR autoprocessing. J. Virol. 69 3878-3884.
199. G. Zybarth, H.G. Kräusslich, K. Partin and C. Carter (1994) Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain. J. Virol. 68 240-250.